Literature DB >> 30066310

Drug Repurposing in Parkinson's Disease.

Dilan Athauda1, Thomas Foltynie2.   

Abstract

The development of an intervention to slow or halt disease progression remains the greatest unmet therapeutic need in Parkinson's disease. Given the number of failures of various novel interventions in disease-modifying clinical trials in combination with the ever-increasing costs and lengthy processes for drug development, attention is being turned to utilizing existing compounds approved for other indications as novel treatments in Parkinson's disease. Advances in rational and systemic drug repurposing have identified a number of drugs with potential benefits for Parkinson's disease pathology and offer a potentially quicker route to drug discovery. Here, we review the safety and potential efficacy of the most promising candidates repurposed as potential disease-modifying treatments for Parkinson's disease in the advanced stages of clinical testing.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30066310     DOI: 10.1007/s40263-018-0548-y

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  138 in total

Review 1.  Drug repositioning: identifying and developing new uses for existing drugs.

Authors:  Ted T Ashburn; Karl B Thor
Journal:  Nat Rev Drug Discov       Date:  2004-08       Impact factor: 84.694

Review 2.  Can the pharmaceutical industry reduce attrition rates?

Authors:  Ismail Kola; John Landis
Journal:  Nat Rev Drug Discov       Date:  2004-08       Impact factor: 84.694

3.  The current and projected economic burden of Parkinson's disease in the United States.

Authors:  Stacey L Kowal; Timothy M Dall; Ritashree Chakrabarti; Michael V Storm; Anjali Jain
Journal:  Mov Disord       Date:  2013-02-21       Impact factor: 10.338

4.  Overcoming Drug Development Bottlenecks With Repurposing: Old drugs learn new tricks.

Authors:  Stephen M Strittmatter
Journal:  Nat Med       Date:  2014-06       Impact factor: 53.440

5.  Innovation in the pharmaceutical industry: New estimates of R&D costs.

Authors:  Joseph A DiMasi; Henry G Grabowski; Ronald W Hansen
Journal:  J Health Econ       Date:  2016-02-12       Impact factor: 3.883

6.  Amantadine in Parkinson's disease. Review of more than two years' experience.

Authors:  R S Schwab; D C Poskanzer; A C England; R R Young
Journal:  JAMA       Date:  1972-11-13       Impact factor: 56.272

Review 7.  The ongoing pursuit of neuroprotective therapies in Parkinson disease.

Authors:  Dilan Athauda; Thomas Foltynie
Journal:  Nat Rev Neurol       Date:  2014-12-02       Impact factor: 42.937

8.  Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.

Authors:  E R Dorsey; R Constantinescu; J P Thompson; K M Biglan; R G Holloway; K Kieburtz; F J Marshall; B M Ravina; G Schifitto; A Siderowf; C M Tanner
Journal:  Neurology       Date:  2006-11-02       Impact factor: 9.910

9.  The Drug Repurposing Hub: a next-generation drug library and information resource.

Authors:  Steven M Corsello; Joshua A Bittker; Zihan Liu; Joshua Gould; Patrick McCarren; Jodi E Hirschman; Stephen E Johnston; Anita Vrcic; Bang Wong; Mariya Khan; Jacob Asiedu; Rajiv Narayan; Christopher C Mader; Aravind Subramanian; Todd R Golub
Journal:  Nat Med       Date:  2017-04-07       Impact factor: 53.440

Review 10.  Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments.

Authors:  Panchanan Maiti; Jayeeta Manna; Gary L Dunbar
Journal:  Transl Neurodegener       Date:  2017-10-25       Impact factor: 8.014

View more
  17 in total

1.  Targeting Age-Related Neurodegenerative Diseases by AAV-Mediated Gene Therapy.

Authors:  Umut Cagin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Pharmacokinetics, Safety, and Tolerability of Orally Administered Ursodeoxycholic Acid in Patients With Parkinson's Disease-A Pilot Study.

Authors:  Abhishek G Sathe; Paul Tuite; Chi Chen; Yiwei Ma; Wei Chen; James Cloyd; Walter C Low; Clifford J Steer; Byeong-Yeul Lee; Xiao-Hong Zhu; Lisa D Coles
Journal:  J Clin Pharmacol       Date:  2020-02-12       Impact factor: 3.126

Review 3.  Recycled Translation: Repurposing Drugs for Stroke.

Authors:  Samantha E Spellicy; David C Hess
Journal:  Transl Stroke Res       Date:  2022-02-26       Impact factor: 6.829

Review 4.  Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders.

Authors:  Dharmendra Kumar Khatri; Amey Kadbhane; Monica Patel; Shweta Nene; Srividya Atmakuri; Saurabh Srivastava; Shashi Bala Singh
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-04-08

5.  Bioresorbable thin-film silicon diodes for the optoelectronic excitation and inhibition of neural activities.

Authors:  Yunxiang Huang; Yuting Cui; Hanjie Deng; Jingjing Wang; Rongqi Hong; Shuhan Hu; Hanqing Hou; Yuanrui Dong; Huachun Wang; Junyu Chen; Lizhu Li; Yang Xie; Pengcheng Sun; Xin Fu; Lan Yin; Wei Xiong; Song-Hai Shi; Minmin Luo; Shirong Wang; Xiaojian Li; Xing Sheng
Journal:  Nat Biomed Eng       Date:  2022-09-05       Impact factor: 29.234

6.  Virtual screening and drug repurposing experiments to identify potential novel selective MAO-B inhibitors for Parkinson's disease treatment.

Authors:  Luminita Crisan; Daniela Istrate; Alina Bora; Liliana Pacureanu
Journal:  Mol Divers       Date:  2020-11-25       Impact factor: 2.943

Review 7.  The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability.

Authors:  Christine Girges; Nirosen Vijiaratnam; Dilan Athauda; Grace Auld; Sonia Gandhi; Thomas Foltynie
Journal:  Drugs Aging       Date:  2021-03-19       Impact factor: 3.923

Review 8.  Current Concepts and Controversies in the Management of REM Sleep Behavior Disorder.

Authors:  E Matar; S J McCarter; E K St Louis; S J G Lewis
Journal:  Neurotherapeutics       Date:  2021-01-06       Impact factor: 7.620

Review 9.  Profile of inhaled levodopa and its potential in the treatment of Parkinson's disease: evidence to date.

Authors:  Ami B Patel; Joohi Jimenez-Shahed
Journal:  Neuropsychiatr Dis Treat       Date:  2018-11-02       Impact factor: 2.570

Review 10.  Repurposing Drugs to Treat Heart and Brain Illness.

Authors:  Maranda S Cantrell; Alejandro Soto-Avellaneda; Jackson D Wall; Aaron D Ajeti; Brad E Morrison; Lisa R Warner; Owen M McDougal
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.